Microbio Co Ltd
12
1
1
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
25%
1 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Clinical Performance Study of Microbio InfectID-BSI for Detection of Bacteria and Yeast With Patient Blood Samples
Role: lead
A Randomized, Placebo Controlled Study to Evaluate the Safety and Potential Efficacy of MS-20 in Combination with Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Role: lead
MS-20 on Patients With Ulcerative Colitis(UC)
Role: collaborator
MS-20 on Gut Microbiota and Risk/Severity of Cachexia in Pancreatic Cancer Patients
Role: collaborator
Postbiotic MBS and Metformin Combination in Patients With T2DM
Role: lead
Exploratory Study to Evaluate the Application of NLAC Cream in Adults With Atopic Dermatitis
Role: lead
Exploratory Study to Evaluate the Application of NLAC Cream in Adults With Plaque Psoriasis
Role: lead
The Impact of MS-20 on Gut Microbiota Composition in Adult Individuals
Role: lead
A Trial of MB-6 for Reduction of Neutropenia Induced by Chemotherapy in Patients With Stage III Colorectal Cancer.
Role: lead
A Trial to Evaluate Safety, Tolerability, PK and Antiviral Activity of MB-110 in Hepatitis C Virus Infected Patients
Role: lead
A Phase II Trial of MB-6 Plus FOLFOX4 for Metastatic Colorectal Cancer (FDA IND 103675)
Role: lead
Evaluation of Quality of Life and Survival With MS-20 in Patient With Advanced Hepatocellular Carcinoma (FDA IND 74572)
Role: lead
All 12 trials loaded